Rencofilstat is under clinical development by Hepion Pharmaceuticals and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase I drugs for Coronavirus Disease 2019 (COVID-19) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Rencofilstat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rencofilstat overview
Rencofilstat (CRV-431) is under development for the treatment of hepatitis C (HCV), hepatocellular carcinoma, multiple myeloma, prostate cancer, kidney fibrosis, non alcoholic fatty liver disease (NAFLD), liver fibrosis, liver cirrhosis, idiopathic pulmonary fibrosis and cardiac fibrosis. It is administered through oral route. It is being developed based on AI-POWR platform. The drug candidate acts by targeting Pan cyclophilin.
CRV-431 (CPI-43132) is also under development for the treatment of acute lung injury, coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
It was also under development for hepatitis D (HDV) hepatitis B (HBV), non-alcoholic steatohepatitis, HIV-1 co-infection.
Hepion Pharmaceuticals overview
Hepion Pharmaceuticals (Hepion) is a clinical stage biopharmaceutical company. It primarily focuses on the development of therapeutic drugs using artificial intelligence (AI) for the treatment of non-alcoholic steatohepatitis (NASH), fibrotic diseases, hepatocellular carcinoma (HCC), and other chronic diseases. The company’s products are primarily aimed at the healthcare industry, specifically for the treatment of liver-related diseases. Hepion serves patients and healthcare professionals by developing differentiated therapeutic products. The company operates in the US. Hepion is headquartered in Edison, New Jersey, the US.
For a complete picture of Rencofilstat’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
